Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | short review

Drug therapy for recurrent, progressive, atypical, and malignant meningiomas

verfasst von: Prof. Christine Marosi, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Till date, no breakthrough for systemic therapy of recurrent meningiomas has been achieved. The multitude of optional drugs shows that none of them so far could become a standard of care. On the other hand, although the disease is rare, each neurooncological centre has some patients with unmet treatment needs. Cohort studies should be able to answer the question whether meningiomas occur more rarely or do not become symptomatic in individuals undergoing treatment with statins, glitazones, or calcium channel blockers. If found effective, such drugs would be suitable as first line treatment in patients with grade I recurrent meningiomas, because for these indications most probably the long treatment periods appear necessary. For patients who recur with such drugs, targeted therapies could represent further treatment options, whereas cytotoxic drugs with severe side effects such as trabectedin could perhaps be investigated for recurrent malignant meningiomas after all other options.
Literatur
1.
Zurück zum Zitat Pechlivanis I, et al. Evidence level in the treatment of meningioma with focus on the comparison between surgery versus radiotherapy. A review. J Neurosurg Sci. 2011;55(4):319–28.PubMed Pechlivanis I, et al. Evidence level in the treatment of meningioma with focus on the comparison between surgery versus radiotherapy. A review. J Neurosurg Sci. 2011;55(4):319–28.PubMed
2.
Zurück zum Zitat Yang SY, et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry, 2008;79(5):574–80.PubMedCrossRef Yang SY, et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry, 2008;79(5):574–80.PubMedCrossRef
3.
Zurück zum Zitat Grunberg SM, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33.PubMedCrossRef Grunberg SM, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33.PubMedCrossRef
4.
Zurück zum Zitat Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–73.PubMedCrossRef Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–73.PubMedCrossRef
5.
Zurück zum Zitat Johnson DR, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530–5.PubMedCrossRef Johnson DR, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530–5.PubMedCrossRef
6.
Zurück zum Zitat Stewart DJ, et al. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol. 1995;24(2):189–94.PubMedCrossRef Stewart DJ, et al. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol. 1995;24(2):189–94.PubMedCrossRef
7.
Zurück zum Zitat Gupta V, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106(3):455–62.PubMedCrossRef Gupta V, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106(3):455–62.PubMedCrossRef
8.
Zurück zum Zitat Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271–6.PubMedCrossRef Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271–6.PubMedCrossRef
9.
Zurück zum Zitat Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62(7):1210–2.PubMedCrossRef Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62(7):1210–2.PubMedCrossRef
10.
Zurück zum Zitat Kaba SE, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40(2):271–5.PubMedCrossRef Kaba SE, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40(2):271–5.PubMedCrossRef
11.
Zurück zum Zitat Muhr C, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269–76.PubMed Muhr C, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269–76.PubMed
12.
Zurück zum Zitat Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent world health organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146–51.PubMedCrossRef Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent world health organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146–51.PubMedCrossRef
13.
Zurück zum Zitat Shamah SM, et al. Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res. 1997;57(18):4141–7.PubMed Shamah SM, et al. Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res. 1997;57(18):4141–7.PubMed
14.
Zurück zum Zitat Todo T. et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84(5):852–8 (Discussion 858–9).PubMedCrossRef Todo T. et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84(5):852–8 (Discussion 858–9).PubMedCrossRef
15.
Zurück zum Zitat Nakayama Y. et al. Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma. Noshuyo Byori. 1994;11(2):187–91.PubMed Nakayama Y. et al. Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma. Noshuyo Byori. 1994;11(2):187–91.PubMed
16.
Zurück zum Zitat Adams EF. et al. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. Int J Cancer. 1991;49(3):398–402.PubMedCrossRef Adams EF. et al. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. Int J Cancer. 1991;49(3):398–402.PubMedCrossRef
17.
Zurück zum Zitat Wen PY. et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01–08). Neuro Oncol. 2009;11(6):853–60.PubMedCrossRef Wen PY. et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01–08). Neuro Oncol. 2009;11(6):853–60.PubMedCrossRef
18.
Zurück zum Zitat Reardon DA, et al. Phase II study of gleevec((R)) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;106(2):409–15.PubMedCrossRef Reardon DA, et al. Phase II study of gleevec((R)) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;106(2):409–15.PubMedCrossRef
19.
Zurück zum Zitat Norden AD, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–7.PubMedCrossRef Norden AD, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–7.PubMedCrossRef
20.
Zurück zum Zitat Puchner MJ, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21(12):2445–6.PubMedCrossRef Puchner MJ, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21(12):2445–6.PubMedCrossRef
21.
22.
Zurück zum Zitat Schmid S, et al. Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery. 2010;67(6):1703–8 (Discussion 1708).PubMedCrossRef Schmid S, et al. Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery. 2010;67(6):1703–8 (Discussion 1708).PubMedCrossRef
23.
Zurück zum Zitat Goutagny S, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011;22(4):990–1.PubMedCrossRef Goutagny S, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011;22(4):990–1.PubMedCrossRef
24.
Zurück zum Zitat Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9(3):231–40.PubMedCrossRef Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9(3):231–40.PubMedCrossRef
25.
Zurück zum Zitat Karlsson AE, et al. Estramustine-binding protein in meningioma. Acta Neuropathol. 1999;98(2):135–40.PubMedCrossRef Karlsson AE, et al. Estramustine-binding protein in meningioma. Acta Neuropathol. 1999;98(2):135–40.PubMedCrossRef
26.
Zurück zum Zitat Ragel BT, et al. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus. 2007;23(4):E10.PubMedCrossRef Ragel BT, et al. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus. 2007;23(4):E10.PubMedCrossRef
27.
Zurück zum Zitat Park YS, et al. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol. 2002;507:387–93.PubMedCrossRef Park YS, et al. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol. 2002;507:387–93.PubMedCrossRef
28.
Zurück zum Zitat Park YS, et al. Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells. Planta Med. 2002;68(5):397–401.PubMedCrossRef Park YS, et al. Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells. Planta Med. 2002;68(5):397–401.PubMedCrossRef
29.
Zurück zum Zitat Gehring S, et al. Cytotoxic effects of statins and thiazolidinediones on meningioma cells. J Neurooncol. 2011;102(3):383–93.PubMedCrossRef Gehring S, et al. Cytotoxic effects of statins and thiazolidinediones on meningioma cells. J Neurooncol. 2011;102(3):383–93.PubMedCrossRef
30.
Zurück zum Zitat Tapia-Perez JH, et al. Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol. 2011;67(5):1193–201.PubMedCrossRef Tapia-Perez JH, et al. Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol. 2011;67(5):1193–201.PubMedCrossRef
31.
Zurück zum Zitat Bil J, et al. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett. 2010;288(1):57–67.PubMedCrossRef Bil J, et al. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett. 2010;288(1):57–67.PubMedCrossRef
32.
Zurück zum Zitat Ledezma E, et al. Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells. Melanoma Res. 2009;19(2):69–74.PubMedCrossRef Ledezma E, et al. Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells. Melanoma Res. 2009;19(2):69–74.PubMedCrossRef
33.
Zurück zum Zitat Fuentes S, et al. Hydroxyurea treatment for unresectable meningioma. Neurochirurgie. 2004;50(4):461–7.PubMedCrossRef Fuentes S, et al. Hydroxyurea treatment for unresectable meningioma. Neurochirurgie. 2004;50(4):461–7.PubMedCrossRef
34.
Zurück zum Zitat Hahn BM, et al. Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol. 2005;74(2):157–65.PubMedCrossRef Hahn BM, et al. Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol. 2005;74(2):157–65.PubMedCrossRef
35.
Zurück zum Zitat Loven D, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67(1–2):221–6.PubMedCrossRef Loven D, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67(1–2):221–6.PubMedCrossRef
36.
Zurück zum Zitat Mason WP, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97(2):341–6.PubMedCrossRef Mason WP, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97(2):341–6.PubMedCrossRef
37.
Zurück zum Zitat Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000;49(2):165–70.PubMedCrossRef Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000;49(2):165–70.PubMedCrossRef
38.
Zurück zum Zitat Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18(5):495–9.PubMedCrossRef Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18(5):495–9.PubMedCrossRef
39.
Zurück zum Zitat Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9(2):156–8.PubMedCrossRef Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9(2):156–8.PubMedCrossRef
40.
Zurück zum Zitat Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma: a retrospective case series. Neuro-Oncology. 2011;13:42.CrossRef Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma: a retrospective case series. Neuro-Oncology. 2011;13:42.CrossRef
Metadaten
Titel
Drug therapy for recurrent, progressive, atypical, and malignant meningiomas
verfasst von
Prof. Christine Marosi, M.D.
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0012-5

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe